Breast cancer metastatic+2
Not recruitingStudy on Trastuzumab Emtansine, Pertuzumab, and Atezolizumab for Patients with HER2-Positive Metastatic Cancer Who Benefited from Previous Treatment
Study on Trastuzumab Emtansine, Pertuzumab, and Atezolizumab for Patients with HER2-Positive Metastatic Cancer Who Benefited from Previous Treatment
- Disease:Breast cancer metastaticNeoplasm malignant+1
- Substances:AtezolizumabPertuzumab+1
Belgium- Participants:18–64 years · 65+ years
- Substances:Atezolizumab
- Sponsor:F. Hoffmann-La Roche AG















